Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer

Oncologist - United States
doi 10.1634/theoncologist.2019-0299

Related search